Latest filings (excl ownership)
6-K
Current report (foreign)
21 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
Immatics Announces Proposed Public Offering
22 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
6-K
Current report (foreign)
14 Nov 23
6-K
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
8 Nov 23
6-K
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
24 Oct 23
EFFECT
Notice of effectiveness
14 Sep 23
424B3
Prospectus supplement
13 Sep 23
6-K
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
11 Sep 23
CORRESP
Correspondence with SEC
11 Sep 23
UPLOAD
Letter from SEC
29 Aug 23
F-3
Shelf registration (foreign)
25 Aug 23
6-K
Current report (foreign)
17 Aug 23
6-K
Current report (foreign)
10 Aug 23
6-K
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
24 Jul 23
6-K
Current report (foreign)
20 Jun 23
6-K
CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF
26 May 23
6-K
Current report (foreign)
16 May 23
6-K
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
2 May 23
6-K
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
1 May 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
Current report (foreign)
21 Mar 23
6-K
Current report (foreign)
13 Mar 23
6-K
Current report (foreign)
9 Jan 23
6-K
Current report (foreign)
17 Nov 22
6-K
Next-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors
10 Nov 22
6-K
Current report (foreign)
18 Oct 22
6-K
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
12 Oct 22
424B5
Prospectus supplement for primary offering
11 Oct 22
424B5
Prospectus supplement for primary offering
11 Oct 22
6-K
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
11 Oct 22
6-K
Current report (foreign)
12 Sep 22
6-K
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
23 Aug 22
6-K
Current report (foreign)
9 Aug 22
6-K
Current report (foreign)
30 Jun 22
S-8
Registration of securities for employees
24 Jun 22
6-K
Current report (foreign)
14 Jun 22
6-K
Current report (foreign)
13 Jun 22
Latest ownership filings
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
SC 13G
ATHOS KG
16 Aug 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
dievini Hopp BioTech holding GmbH & Co KG
10 Feb 23
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
7 Feb 23
SC 13G
Nantahala Capital Management, LLC
14 Feb 22
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 22
SC 13G/A
dievini Hopp BioTech holding GmbH & Co KG
11 Feb 22
SC 13G
ARYA SCIENCES HOLDINGS
16 Feb 21
SC 13G
dievini Hopp BioTech holding GmbH & Co KG
12 Feb 21
SC 13G/A
Nantahala Capital Management, LLC
10 Aug 20